MOUNTAIN VIEW, Calif.,
Feb. 13, 2017 /PRNewswire/
-- Omnicell, Inc. (NASDAQ: OMCL) today announced that DCH
Health System in west Alabama has
chosen Omnicell® IV solutions to support their sterile
compounding operation to enhance patient safety and reduce pharmacy
outsourcing costs.
DCH has partnered with Omnicell to implement the full suite of
IV compounding technology across its health system –
i.v.STATIONTM for non-hazardous robotic compounding,
i.v.STATION ONCOTM for hazardous robotic compounding,
and i.v.SOFT® Assist for semi-automated compounding. DCH
will also implement the newest offering from Omnicell, the Robotic
IV Insourcing SolutionTM (RIIS). This unique program
combines advanced robotic technology, data and expertly trained
pharmacy technician staff into a comprehensive, turnkey package
that provides a streamlined path for hospitals to insource their
sterile compounding.
"We needed a cost effective way to prepare IV medications that
supports our patient safety initiatives," said Tim Martin, PharmD, pharmacy director at
DCH Regional Medical Center. "Omnicell's full suite of IV
automation technology, including novel programs like RIIS, gives us
the tools and resources we need to create a safer, more accurate
and ultimately more cost-effective IV compounding operation."
IV medications are complicated and expensive, representing 80
percent of drug spend and 56 percent of overall pharmacy
costs.1
"The challenges of IV compounding—primarily ensuring doses are
prepared safely and accurately while complying with increasingly
complex regulations—have been deemed too much for some health
systems, so they've decided to 'outsource' the problem, and they
are willing to pay a significant premium to do so," said
Douglas Descalzi, vice president and
general manager of IV Solutions at Omnicell. "We've taken these
challenges head-on, creating a comprehensive, turnkey approach to
insource sterile compounding that leverages operational spend and
can be cash flow positive immediately."
Through RIIS, DCH will also have access to novel data services,
including REINVENT, a first-of-a-kind global clinical registry that
utilizes IV preparation data from sites around the world to help
users track performance, identify best practices and gather
insights to maximize the value of IV automation technology.
Omnicell's Formulary Tool Kit will provide the health system access
to cGMP stability studies to extend beyond use dates using a
proven, systematic, repeatable process.
"At Omnicell, we are committed to helping our customers drive
improved outcomes. That's the bottom line. Our advanced IV robotic
technology is a key piece of that equation, but equally as
important are the novel tools, applications support and expertise
we provide to drive desired outcomes and enhance patient safety,
improve therapy, reduce cost, and facilitate compliance in their IV
room," Descalzi said.
About DCH Health System
The DCH Health System, based in Tuscaloosa, Ala., operates DCH Regional
Medical Center, a 583-bed regional trauma and referral center; and
Northport Medical Center, a 250-bed community hospital with
inpatient rehabilitation and psychiatric units. Fayette Medical
Center, a rural hospital and nursing home, is operated under a
long-term lease.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create
safer and more efficient ways to manage medications and supplies
across all care settings. As a leader in medication and supply
dispensing automation, central pharmacy automation, IV robotics,
analytics software, and medication adherence and packaging systems,
Omnicell is focused on improving care across the entire healthcare
continuum—from the acute care hospital setting, to post-acute
skilled nursing and long-term care facilities, to the patient's
home.
Over 4,000 customers worldwide use Omnicell®
automation and analytics solutions to increase operational
efficiency, reduce medication errors, deliver actionable
intelligence and improve patient safety.
Omnicell's innovative medication adherence solutions, used by
over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve
patient adherence to prescriptions, helping to reduce costly
hospital readmissions.
Recent Omnicell acquisitions, including Ateb, add distinct
capabilities, particularly in central pharmacy, IV robotics, and
pharmacy software, creating the broadest medication management
product portfolio in the industry.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
OMCL-G
Footnotes:
1 Results from the 2013 ASHP National Survey: The
Current State of Pharmacy Practice in Hospitals presented at the
2013 ASHP Midyear Clinical Meeting; Aesynt analysis of pre-mixed,
frozen premixed, and add-a-vial systems, March 2014.
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products,
technology etc.) are issued exclusively by PR Newswire and are
immediately thereafter posted on the company's external website,
omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks
of Omnicell, Inc.
- All other brand or product names may be trademarks or
registered trademarks of their respective companies.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dch-health-system-partners-with-omnicell-to-automate-sterile-compounding-with-robotic-iv-insourcing-solution-riis-300406104.html
SOURCE Omnicell, Inc.